Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation
Overview
Authors
Affiliations
Background: End-stage liver disease (ESLD) is not considered a risk factor for atherosclerotic cardiovascular disease (ASCVD). However, lifestyle characteristics commonly associated with increased ASCVD risk are highly prevalent in ESLD. Emerging literature shows a high burden of asymptomatic coronary artery disease (CAD) in patients with ESLD and a high ASCVD risk in liver transplantation (LT) recipients. Coronary artery calcium score (CAC) is a noninvasive test providing reliable CAD risk stratification. We implemented an LT evaluation protocol with CAC playing a central role in triaging and determining the need for further CAD assessment. Here, we inform our results from this early experience.
Methods: Patients with ESLD referred for LT evaluation were prospectively studied. We compared accuracy of CAC against that of CAD risk factors/scores, troponin I, dobutamine stress echocardiogram (DSE), and single-photon emission computed tomography (SPECT) to detect coronary stenosis ≥70 (CAD ≥ 70) per left heart catheterization (LHC). Thirty-day post-LT cardiac outcomes were also analyzed.
Results: One hundred twenty-four of 148 (84%) patients underwent CAC, 106 (72%) DSE/SPECT, and 50 (34%) LHC. CAC ≥ 400 was found in 35 (28%), 100 to 399 in 17 (14%), and <100 in 72 (58%). LHC identified CAD ≥ 70% in 8 of 29 (28%), 2 of 9 (22%), and 0 of 4, respectively. Two acute coronary syndromes occurred after LT in a patient with CAC 811 (CAD < 70%), and one with CAC 347 (CAD ≥ 70%). No patients with CAC < 100 presented with acute coronary syndrome after LT. When using CAD ≥ 70% as primary endpoint of LT evaluation, CAC ≥ 346 was the only test showing predictive usefulness (negative predictive value 100%).
Conclusions: CAC is a promising tool to guide CAD risk stratification and need for LHC during LT evaluation. Patients with a CAC < 100 can safely undergo LT without the need for LHC or cardiac stress testing, whereas a CAC < 346 accurately rules out significant CAD stenosis (≥70%) on LHC, outperforming other CAD risk-stratification strategies.
Sogbe M, Hummer B, Stine J, Lizaola-Mayo B, Forman D, Vargas H Dig Dis Sci. 2025; .
PMID: 39966289 DOI: 10.1007/s10620-025-08893-4.
Ramos H, Altieri M Rev Fac Cien Med Univ Nac Cordoba. 2024; 81(2):432-452.
PMID: 38941220 PMC: 11370871. DOI: 10.31053/1853.0605.v81.n2.44419.
Assessment and Management of Ischaemic Heart Disease in Non-Cardiac Surgery.
Morgan H, Ezad S, Rahman H, De Silva K, Partridge J, Perera D Heart Int. 2024; 17(2):19-26.
PMID: 38419719 PMC: 10898586. DOI: 10.17925/HI.2023.17.2.19.
Alkadhi H, Baettig E, Biondo A, Francone M, Manka R Eur Radiol. 2023; 33(12):8436-8438.
PMID: 37432403 DOI: 10.1007/s00330-023-09893-6.
Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.
Girleanu I, Trifan A, Huiban L, Muzica C, Petrea O, Singeap A Life (Basel). 2022; 12(7).
PMID: 35888123 PMC: 9315506. DOI: 10.3390/life12071036.